Parkinson’s Disease – Landscape & Forecast – Disease Landscape & Forecast

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ABBV-951, IPX203); two new rescue therapies for “off” periods are available (i.e., Inbrija, Kynmobi); and several new adjunctive agents for motor symptoms have launched (i.e., Nourianz, Xadago, Ongentys) or are in late-phase development (e.g., tavapadon). These and other product launches will add another layer of complexity to an already complicated treatment algorithm, with the potential to meaningfully increase sales of PD therapies. However, given the cost-sensitivity of PD patients and the widespread availability of generic and—for many patients—therapeutically adequate agents, new PD brands will enter a market of intensifying competition and access challenges.

Questions Answered:

  • What will be the impact of forthcoming levodopa reformulations? Will they alter the PD treatment paradigm or be sidelined by access hurdles and/or physician resistance?
  • What is the market opportunity for recently launched and emerging agents targeting key nonmotor symptoms in PD?
  • How do neurologists differentiate among levodopa-adjunct therapies for motor fluctuations and dyskinesia, and which of these therapies will enjoy the greatest clinical and commercial success in this highly generic market?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 26 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other DRG research.

Epidemiology: Total, diagnosed, and drug-treated prevalent cases of PD by country.

Emerging therapies: Phase II: 21 drugs; Phase III: 7 drugs; preregistration: 1 drug.

Market forecast features: Ten-year, annualized, drug-level sales and patient shares of key PD therapies through 2029, segmented by brands/generics.

Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Eisai, Hisamitsu Pharmaceutical, Kyowa Hakko Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Takeda, Teva, Theravance Biopharma, UCB, US WorldMeds, Zambon Pharma.

Key drugs: levodopa, amantadine, ampreloxetine, apomorphine, ABBV-951, AP-CD/LD, Duodopa/Duopa, entacapone, Gocovri, Haruropi Tape, Inbrija, IPX203, Kynmobi, Lecigon, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B001, rasagiline, ropinirole, Rytary, selegiline, tavapadon, Trerief, Xadago.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Parkinson's Disease - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q3 2021
        • September 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
        • November 2020
        • October 2020
      • Q3 2020
        • July 2020
    • Key Findings
      • Parkinson's Disease - Key Findings - February 2021
        • July 2020
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for Parkinson's Disease: 2019
        • Market Share of Drug Classes for Parkinson's Disease: 2029
        • Parkinson's Disease SWOT Analysis
      • COVID-19: Market Forecast Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Parkinson's Disease?
          • What Factors Are Constraining the Market for Parkinson's Disease?
          • Major-Market Sales by Class in Parkinson's Disease: 2019-2029
          • Major-Market Patient Share by Class in Parkinson's Disease: 2019-2029
          • Total Sales by Region in Parkinson's Disease: 2019-2029
          • Major-Market Sales of Emerging Therapies in Parkinson's Disease: 2019-2029
          • Major-Market Sales of Key Current Brands in Parkinson's Disease: 2019-2029
        • Drug-Class-Specific Trends
          • Major-Market Sales of Key Dopamine Precursors in Parkinson's Disease: 2019-2029
          • U.S. Patient Share of Key Dopamine Precursors in Parkinson's Disease: 2019-2029
          • European Patient Share of Key Dopamine Precursors in Parkinson's Disease: 2019-2029
          • Major-Market Sales of Key Dopamine Agonists in Parkinson's Disease: 2019-2029
          • U.S. Patient Share of Key Dopamine Agonists in Parkinson's Disease: 2019-2029
          • Japanese Patient Share of Key Dopamine Agonists in Parkinson's Disease: 2019-2029
          • Major-Market Sales of MAO-B Inhibitors in Parkinson's Disease: 2019-2029
          • Major-Market Patient Share of MAO-B Inhibitors in Parkinson's Disease: 2019-2029
          • Major-Market Sales of COMT Inhibitors in Parkinson's Disease: 2019-2029
          • Major-Market Patient Share of COMT Inhibitors in Parkinson's Disease: 2019-2029
          • Major-Market Sales and Patient Share of Istradefylline in Parkinson's Disease: 2019-2029
          • Major-Market Sales of Key Antiglutamatergic Agents in Parkinson's Disease: 2019-2029
          • U.S. Patient Share of Antiglutamatergic Agents in Parkinson's Disease: 2019-2029
          • Major-Market Sales of Acute Rescue Therapies in Parkinson's Disease: 2019-2029
          • U.S. Patient Share of Acute Rescue Therapies in Parkinson's Disease: 2019-2029
          • Major-Market Sales of Antipsychotic Agents in Parkinson's Disease: 2019-2029
          • U.S. Patient Share of Antipsychotic Agents in Parkinson's Disease: 2019-2029
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Etiology
            • Known and Suspected Nongenetic Risk and Protective Factors in Parkinson's Disease
            • Genetic Loci Linked to Familial and/or Sporadic Parkinson's Disease
          • Pathophysiology
            • Molecular and Cellular Processes Implicated in Neuronal Death in Parkinson's Disease
            • Brain Structures Implicated in Movement and Parkinson's Disease
            • Neuronal Circuits Within the Basal Ganglia Implicated in the Control of Normal Movement
            • Changes in Basal Ganglia Circuitry Following the Loss of Substantia Nigra Dopaminergic Neurons Leading to Motor Symptoms of Parkinson's Disease
            • Pathophysiological Processes and Mutant Genes Implicated in Parkinson's Disease
            • Role of Protein Folding and Degradation in Parkinson's Disease
            • Braak Staging System
          • Disease Progression
            • Progression of Clinical Symptoms Associated with Parkinson's Disease
          • Key Pathways and Drug Targets
            • Key Pathways and Drug Targets in Parkinson's Disease
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Total Prevalent Cases of Parkinson's Disease
              • Total Prevalent Cases of Parkinson's Disease: 2019-2029 (thousands)
              • Diagnosed Prevalent Cases of Parkinson's Disease: 2019-2029 (thousands)
              • Drug-Treated Prevalent Cases of Parkinson's Disease: 2019-2029 (thousands)
          • Current Treatment
            • Key Findings
              • Treatment Goals
                • Key Endpoints Used in Clinical Trials for Parkinson's Disease
              • Key Current Therapies
                • Overview
                • Mechanism of Action of Key Current Drug Classes Used for Parkinson's Disease
                • Mechanism of Action of Key Current Drug Classes Used for Parkinson's Disease
                • Current Treatments Used for Parkinson's Disease
                • Market Events Impacting the Use of Key Current Therapies in Parkinson's Disease
                • Advantages and Disadvantages of Dopamine Precursors
                • Expert Insight: Dopamine Precursors
                • Advantages and Disadvantages of Dopamine Agonists
                • Ongoing Clinical Development of the Apomorphine Pump
                • Expert Insight: Dopamine Agonists
                • Advantages and Disadvantages of MAO-B Inhibitors
                • Ongoing Clinical Development of Safinamide
                • Expert Insight: MAO-B Inhibitors
                • Advantages and Disadvantages of COMT Inhibitors
                • Expert Insight: COMT Inhibitors
                • Advantages and Disadvantages of Istradefylline
                • Expert Insight: Adenosine A2A Receptor Antagonists
                • Advantages and Disadvantages of Antiglutamatergic Agents
                • Expert Insight: Antiglutamatergic Agents
                • Advantages and Disadvantages of Acute Rescue Therapies
                • Ongoing Clinical Development of Kynmobi
                • Expert Insight: Acute Rescue Therapies
                • Advantages and Disadvantages of Key Antidementia Agents
                • Expert Insight: Antidementia Agents
                • Advantages and Disadvantages of Antipsychotic Agents
                • Ongoing Clinical Development of Nuplazid
                • Expert Insight: Antipsychotic Agents
                • Advantages and Disadvantages of Other Agents
                • Ongoing Clinical Development of Droxidopa
                • Expert Insight: Other Agents
              • Medical Practice
                • Overview
                • Factors Influencing Drug Selection in Parkinson's Disease
                • Drug Selection in Parkinson's Disease by Disease Severity
                • Drug Selection in Parkinson's Disease for Select Nonmotor Symptoms
                • Treatment Decision Tree for Parkinson's Disease: United States
                • Treatment Decision Tree for Parkinson's Disease: Europe
                • Treatment Decision Tree for Parkinson's Disease: Japan
            • Unmet Need Overview
              • Current and Future Attainment of Unmet Needs in Parkinson's Disease
              • Top Unmet Needs in Parkinson's Disease: Current and Future Attainment
            • Emerging Therapies
              • Key Findings
                • Key Emerging Therapies
                  • Key Therapies in Late-Phase Development for Parkinson's Disease
                  • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Parkinson's Disease
                  • AP-CD/LD Profile
                  • Analysis of the Clinical Development Program for AP-CD/LD
                  • Expert Insight: AP-CD/LD
                  • Expectations for Launch and Sales Opportunity of AP-CD/LD in Parkinson's Disease
                  • IPX203 Profile
                  • Analysis of the Clinical Development Program for IPX203
                  • Expert Insight: IPX203
                  • Expectations for Launch and Sales Opportunity of IPX203 in Parkinson's Disease
                  • ABBV-951 Profile
                  • Analysis of the Clinical Development Program for ABBV-951
                  • Expert Insight: ABBV-951
                  • Expectations for Launch and Sales Opportunity of ABBV-951 in Parkinson's Disease
                  • ND0612 Profile
                  • Analysis of the Clinical Development Program for ND0612
                  • Expert Insight: ND0612
                  • Expert Insight: Levodopa-Carbidopa Pump Therapies
                  • Expectations for Launch and Sales Opportunity of ND0612 in Parkinson's Disease
                  • Lecigon Profile
                  • Analysis of the Clinical Development Program for Lecigon
                  • Expert Insight: Lecigon
                  • Expectations for Launch and Sales Opportunity of Lecigon in Parkinson's Disease
                  • P2B001 Profile
                  • Analysis of the Clinical Development Program for P2B001
                  • Expert Insight: P2B001
                  • Expectations for Launch and Sales Opportunity of P2B001 in Parkinson's Disease
                  • Tavapadon Profile
                  • Analysis of the Clinical Development Program for Tavapadon
                  • Expert Insight: Tavapadon
                  • Expectations for Launch and Sales Opportunity of Tavapadon in Parkinson's Disease
                  • TD-9855 Profile
                  • Analysis of the Clinical Development Program for TD-9855
                  • Expert Insight: TD-9855
                  • Expectations for Launch and Sales Opportunity of TD-9855 in Parkinson's Disease
                • Early-Phase Pipeline Analysis
                  • Select Symptomatic Compounds in Phase II Development for the Motor Symptoms of Parkinson's Disease
                  • Select Symptomatic Compounds in Phase II Development for the Nonmotor Symptoms of Parkinson's Disease
                  • Select Disease-Modifying Compounds in Phase II Development for Parkinson's Disease
                  • Challenges to Developing Disease-Modifying Therapies for Parkinson's Disease
                  • Select Biomarker Studies and Initiatives for Parkinson's Disease
              • Access and Reimbursement Overview
                • Region-Specific Reimbursement Practices
                  • Key Market Access Considerations in Parkinson's Disease: United States
                  • General Reimbursement Environment: United States
                  • Key Market Access Considerations in Parkinson's Disease: EU5
                  • General Reimbursement Environment: EU5
                  • Key Market Access Considerations in Parkinson's Disease: Japan
                  • General Reimbursement Environment: Japan
              • Appendix
                • Parkinson's Disease Bibliography

            launch Related Market Assessment Reports